Skip to main content

Table 1 Pairwise meta-analysis of antibiotics of clinical cure in cSSSI and HAP/VAP in mITT population

From: Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Treatment comparisons

Number of studies

Pairwise meta-analysis Odds ratio (95% CI)

P value

Heterogeneity I2, % (variation in OR attributable to heterogeneity)

cSSSI

 Vancomycin vs Oritavancin

2

0.96 (0.59, 1.56)

0.867

0.0

 Vancomycin vs Daptomycin

4

1.04 (0.79, 1.36)

0.756

0.0

 Vancomycin vs Telavancin

4

0.86 (0.61, 1.24)

0.430

0.0

 Vancomycin vs Tigecycline

3

1.15 (0.79, 1.66)

0.451

0.0

 Vancomycin vs Ceftaroline

4

0.94 (0.71, 1.26)

0.695

0.0

 Vancomycin vs Dalbavancin

2

1.00 (0.77, 1.31)

0.973

0.0

 Vancomycin vs Ceftobiprole

2

0.78 (0.33, 1.82)

0.565

0.0

 Linezolid vs Vancomycin

5

1.23 (1.09, 1.50)

0.006

0.0

 Linezolid vs Dalbavancin

1

0.84 (0.39, 1.82)

0.673

–

 Linezolid vs SXT/rifampicin

1

0.70 (0.16, 2.95)

0.627

–

 Linezolid vs Omadacycline

1

0.36 (0.03, 4.18)

0.417

–

 Linezolid vs Fusidic Acid

1

2.71 (0.83, 8.89)

0.099

–

 Linezolid vs JNJ-Q2

1

0.95 (0.45, 1.94)

0.682

–

 Linezolid vs Tedizolid

2

1.09 (0.58, 2.02)

0.780

0.0

 Linezolid vs Teicoplanin

1

0.52 (0.15, 1.79)

0.234

–

HAP/VAP

 Vancomycin vs Telavancin

2

1.02 (0.85, 1.23)

0.822

0.0

 Vancomycin vs Vancomycin/rifampicin

1

1.49 (0.72, 3.06)

0.278

–

 Vancomycin vs Quinupristin/dalfopristin

1

1.03 (0.71, 1.51)

0.858

–

 Linezolid vs Vancomycin

8

1.11 (0.91, 1.34)

0.301

0.0

 Linezolid vs Ceftobiprole

1

0.53 (0.17, 1.57)

0.251

–

 Linezolid vs Teicoplanin

1

0.38 (0.07, 2.16)

0.279

–

 Linezolid vs SXT/rifampicin

1

1.77 (0.25, 12.45)

0.562

–

  1. cSSSI complicated skin and soft structure infection, HAP/VAP hospital-acquired or ventilator-associated pneumonia, mITT modified intention-to-treat population, JNJ-Q2 a novel fluoroquinolone, SXT trimethoprim/sulfamethoxazole